TSH Biopharm 대차 대조표 상태

재무 상태 기준 확인 6/6

TSH Biopharm 의 총 주주 지분은 NT$1.5B 이고 총 부채는 NT$0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 NT$1.7B 및 NT$224.2M 입니다. TSH Biopharm 의 EBIT는 NT$118.3M 이며 이자보상배율은 -10.5 입니다. NT$684.2M 의 현금 및 단기 투자금을 보유하고 있습니다.

주요 정보

부채 비율

NT$0

부채

이자 보상 비율	-10.5x
현금	NT$684.18m
주식	NT$1.51b
총 부채	NT$224.20m
총 자산	NT$1.74b

최근 재무 상태 업데이트

업데이트 없음

Recent updates

Weak Financial Prospects Seem To Be Dragging Down TSH Biopharm Corporation Limited (GTSM:8432) Stock

Feb 18

Is TSH Biopharm Corporation Limited (GTSM:8432) An Attractive Dividend Stock?

Jan 21

TSH Biopharm's (GTSM:8432) Shareholders Are Down 26% On Their Shares

Dec 16

재무 상태 분석

단기부채: 8432 의 단기 자산 ( NT$1.2B )이 단기 부채( NT$222.3M ).

장기 부채: 8432 의 단기 자산( NT$1.2B )이 장기 부채( NT$1.9M ).

부채 대 자본 내역 및 분석

부채 수준: 8432 부채가 없습니다.

부채 감소: 8432 5년 전에 부채가 없었습니다.

부채 범위: 8432 은 부채가 없으므로 영업현금흐름으로 충당할 필요가 없습니다.

이자 보장: 8432 에는 부채가 없으므로 이자 지불에 대한 보장은 문제가 되지 않습니다.

TSH Biopharm 대차 대조표 상태

재무 상태 기준 확인 6/6

주요 정보

최근 재무 상태 업데이트

Recent updates

Second quarter 2024 earnings released: EPS: NT$0.37 (vs NT$0.48 in 2Q 2023)

TSH Biopharm Corporation Limited to Report Q2, 2024 Results on Aug 07, 2024

Upcoming dividend of NT$1.28 per share

Dividend reduced to NT$1.28

TSH Biopharm Corporation Limited Announces Appointment of Two Additional Members of Audit Committee

First quarter 2024 earnings released: EPS: NT$1.07 (vs NT$0.28 in 1Q 2023)

TSH Biopharm Corporation Limited to Report Q1, 2024 Results on May 06, 2024

TSH Biopharm Corporation Limited Appoints Jung-Liang Kao as CFO on April 1, 2024

New minor risk - Share price stability

Full year 2023 earnings released: EPS: NT$1.61 (vs NT$1.61 in FY 2022)

TSH Biopharm Corporation Limited, Annual General Meeting, May 24, 2024

Investor sentiment improves as stock rises 15%

TSH Biopharm Corporation Limited Announces the Change of Financial Officer, Effective on January 1, 2024

Third quarter 2023 earnings released: EPS: NT$0.44 (vs NT$0.47 in 3Q 2022)

Investor sentiment improves as stock rises 15%

Second quarter 2023 earnings released: EPS: NT$0.48 (vs NT$0.42 in 2Q 2022)

Upcoming dividend of NT$1.60 per share at 3.5% yield

Tsh Biopharm Corporation Limited Announces the Change of Audit Committee Members

Full year 2022 earnings released: EPS: NT$1.61 (vs NT$1.23 in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: NT$0.47 (vs NT$0.26 in 3Q 2021)

Second quarter 2022 earnings released: EPS: NT$0.42 (vs NT$0.34 in 2Q 2021)

TSH Biopharm Corporation Limited Announces Board Appointments

Investor sentiment improved over the past week

Upcoming dividend of NT$1.50 per share

TSH Biopharm Corporation Limited Announces Cash Dividends, Payable on July 8, 2022

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Less than half of directors are independent

TSH Biopharm Corporation Limited, Annual General Meeting, May 25, 2022

TSH Biopharm Corporation Limited Announces Resignation of Yi-Min Wang from Audit Committee and Remuneration Committee

Third quarter 2021 earnings released: EPS NT$0.26 (vs NT$0.40 in 3Q 2020)

Investor sentiment improved over the past week

Upcoming dividend of NT$1.80 per share

Second quarter 2021 earnings released: EPS NT$0.34 (vs NT$0.21 in 2Q 2020)

First quarter 2021 earnings released: EPS NT$0.25 (vs NT$0.62 in 1Q 2020)

Full year 2020 earnings released: EPS NT$1.60 (vs NT$2.22 in FY 2019)

TSH Biopharm Corporation Limited, Annual General Meeting, May 28, 2021

Full year 2020 earnings released: EPS NT$1.60 (vs NT$2.22 in FY 2019)

New 90-day low: NT$52.70

Weak Financial Prospects Seem To Be Dragging Down TSH Biopharm Corporation Limited (GTSM:8432) Stock

New 90-day low: NT$57.40

Is TSH Biopharm Corporation Limited (GTSM:8432) An Attractive Dividend Stock?

New 90-day low: NT$58.20

TSH Biopharm's (GTSM:8432) Shareholders Are Down 26% On Their Shares

New 90-day low: NT$58.90

New 90-day low: NT$61.70

Third quarter earnings released

New 90-day low: NT$61.90

New 90-day low - NT$63.00

New 90-day low - NT$65.30

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

건강한 기업 발견하기